# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

> **NCT07540910** · PHASE1 · RECRUITING · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 98 (estimated)

## Conditions studied

- Chronic Inducible Urticaria
- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** EDP-978
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07540910
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07540910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07540910, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07540910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*